GlobeNewswire: Adaptimmune Therapeutics plc Contains the last 10 of 226 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T14:48:02ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2022/05/16/2444402/0/en/Preclinical-Proof-of-Concept-Data-Supporting-Future-Clinical-Development-of-Two-New-Cell-Therapies-Being-Presented-by-Adaptimmune-at-ASGCT.html?f=22&fvtc=4&fvtv=25875Preclinical Proof-of-Concept Data Supporting Future Clinical Development of Two New Cell Therapies Being Presented by Adaptimmune at ASGCT2022-05-16T21:00:00Z<![CDATA[- New next-gen SPEAR T-cells (ADP-A2M4N7X19) designed to enhance depth and durability of clinical response demonstrated enhanced proliferation, survival, and recruitment of immune cells in vitro -]]>https://www.globenewswire.com/news-release/2022/05/09/2438472/0/en/Adaptimmune-Reports-First-Quarter-Financial-Results-and-Business-Update.html?f=22&fvtc=4&fvtv=25875Adaptimmune Reports First Quarter Financial Results and Business Update2022-05-09T11:30:00Z<![CDATA[- Pooled data from Cohort 1 of the SPEARHEAD-1 trial and the Phase 1 trial of afami-cel in patients with sarcoma to be presented as a poster at ASCO -]]>https://www.globenewswire.com/news-release/2022/05/04/2435613/0/en/Adaptimmune-Announces-Appointment-of-Joanna-Brewer-as-Chief-Scientific-Officer.html?f=22&fvtc=4&fvtv=25875Adaptimmune Announces Appointment of Joanna Brewer as Chief Scientific Officer2022-05-04T12:00:00Z<![CDATA[PHILADELPHIA and OXFORDSHIRE, United Kingdom, May 04, 2022 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announces the appointment of Dr. Joanna (Jo) Brewer as Chief Scientific Officer (CSO) effective immediately.]]>https://www.globenewswire.com/news-release/2022/04/28/2432023/0/en/Adaptimmune-to-Report-Q1-2022-Financial-Results-and-Business-Updates-on-Monday-May-9-2022.html?f=22&fvtc=4&fvtv=25875Adaptimmune to Report Q1 2022 Financial Results and Business Updates on Monday, May 9, 20222022-04-28T20:30:00Z<![CDATA[PHILADELPHIA and OXFORDSHIRE, United Kingdom, April 28, 2022 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, will report financial results and provide business updates for the first quarter ended March 31, 2022, before the US markets open on Monday, May 9, 2022. Following the announcement, the Company will host a live teleconference and webcast at 8:00 a.m. EDT (1:00 p.m. BST) that same day.]]>https://www.globenewswire.com/news-release/2022/04/08/2419433/0/en/Adaptimmune-Presents-MAGE-A4-Expression-Data-from-its-Screening-Protocol-at-AACR-Confirming-Expression-Across-a-Broad-Range-of-Solid-Tumors.html?f=22&fvtc=4&fvtv=25875Adaptimmune Presents MAGE-A4 Expression Data from its Screening Protocol at AACR Confirming Expression Across a Broad Range of Solid Tumors2022-04-08T17:00:00Z<![CDATA[- Data from multiple solid tumor indications confirms that MAGE-A4 is a broadly expressed cancer target for SPEAR T-cell therapy -]]>https://www.globenewswire.com/news-release/2022/03/14/2402518/0/en/Adaptimmune-Reports-Fourth-Quarter-and-Full-Year-2021-Financial-Results-and-Business-Update.html?f=22&fvtc=4&fvtv=25875Adaptimmune Reports Fourth Quarter and Full Year 2021 Financial Results and Business Update2022-03-14T12:00:00Z<![CDATA[- SPEARHEAD-1 met its primary endpoint - planning for afami-cel BLA submission in Q4 2022 for people with synovial sarcoma -]]>https://www.globenewswire.com/news-release/2022/03/08/2399286/0/en/Adaptimmune-to-Report-Q4-and-Full-Year-2021-Financial-Results-and-Business-Updates-on-Monday-March-14-2022.html?f=22&fvtc=4&fvtv=25875Adaptimmune to Report Q4 and Full Year 2021 Financial Results and Business Updates on Monday, March 14, 20222022-03-08T17:36:03Z<![CDATA[PHILADELPHIA and OXFORDSHIRE, United Kingdom, March 08, 2022 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, will report financial results and provide business updates for the fourth quarter and year ended December 31, 2021, before the US markets open on Monday, March 14, 2022. Following the announcement, the Company will host a live teleconference and webcast at 8:30 a.m. EDT (12:30 p.m. GMT) that same day (details below).]]>https://www.globenewswire.com/news-release/2022/01/26/2373460/0/en/Adaptimmune-Announces-Appointment-of-Cintia-Piccina-as-Chief-Commercial-Officer.html?f=22&fvtc=4&fvtv=25875Adaptimmune Announces Appointment of Cintia Piccina as Chief Commercial Officer2022-01-26T13:00:00Z<![CDATA[PHILADELPHIA and OXFORDSHIRE, United Kingdom, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announces the appointment of Cintia Piccina as Chief Commercial Officer effective January 31, 2022.]]>https://www.globenewswire.com/news-release/2021/11/12/2333258/0/en/Translational-Data-at-SITC-2021-from-Adaptimmune-s-Phase-1-SURPASS-Trial-Indicate-Adding-AKTi-to-Manufacturing-May-Contribute-to-Sustained-Antitumor-Activity-of-Next-gen-SPEAR-T-ce.html?f=22&fvtc=4&fvtv=25875Translational Data at SITC 2021 from Adaptimmune’s Phase 1 SURPASS Trial Indicate Adding AKTi to Manufacturing May Contribute to Sustained Antitumor Activity of Next-gen SPEAR T-cells2021-11-12T12:00:00Z<![CDATA[- Inhibition of AKT signaling during ex vivo T-cell expansion phase of manufacturing provides further proliferative potential and enhanced memory phenotype of next-gen SPEAR T-cells -]]>https://www.globenewswire.com/news-release/2021/11/11/2332690/0/en/Adaptimmune-Reports-Positive-Results-from-its-Pivotal-SPEARHEAD-1-Trial-in-Patients-with-Synovial-Sarcoma-and-MRCLS-at-CTOS.html?f=22&fvtc=4&fvtv=25875Adaptimmune Reports Positive Results from its Pivotal SPEARHEAD-1 Trial in Patients with Synovial Sarcoma and MRCLS at CTOS2021-11-11T14:00:00Z<![CDATA[- SPEARHEAD-1 trial will meet its primary endpoint and data will be used to support BLA filing for afami-cel next year -]]>